Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Bio Path Holdings Inc | BPTH | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 7.62 | 0.00 | 0.00 | 0.00 | 7.62 | 04:57:03 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 6.00 | 9.00 | 3.00 | 33.33% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Bio Path Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 21.97M | 2.88M | $ -8.58M | -14.32 | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 83.50% |
Bio Path News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BPTH Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 10.50 | 15.7432 | 7.53 | 8.16 | 431,331 | -2.88 | -27.43% |
| 1 Month | 12.03 | 15.7432 | 7.53 | 8.85 | 138,410 | -4.41 | -36.66% |
| 3 Months | 11.41 | 15.7432 | 7.53 | 9.84 | 86,999 | -3.79 | -33.22% |
| 6 Months | 14.95 | 17.5259 | 7.53 | 12.98 | 123,317 | -7.33 | -49.03% |
| 1 Year | 10.80 | 73.52 | 1.60 | 16.19 | 1,168,593 | -3.18 | -29.44% |
| 3 Years | 242.00 | 275.40 | 1.60 | 35.84 | 618,666 | -234.38 | -96.85% |
| 5 Years | 528.00 | 638.00 | 1.60 | 78.75 | 428,393 | -520.38 | -98.56% |
Bio Path Description
| Bio-Path Holdings Inc is a United States based clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and in combination with decitabine. The other drug candidates of the company are BP1002 and BP1003. |
